Adlai Nortye Pharmaceutical Co. Ltd. has identified Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Antibody specialist Jounce Therapeutics Inc. and Redx Pharma plc are to merge in an all-share transaction with a value of $425 million, in a deal that will see Redx’s small-molecule cancer and fibrosis drugs absorbing the lion’s share of the combined cash and its shareholders owning 63% of the combined company.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have described pyrimidocyclic derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous and Noonan syndrome.
Acea Therapeutics Inc. and Hangzhou Acea Biosciences Co. Ltd. have described heterocyclic compounds acting as tyrosine kinase inhibitors reported to be useful for the treatment of cancer.
Harbour Biomed Ltd. has received IND clearance by the FDA to initiate clinical trials in the U.S. with HBM-1022, a monoclonal antibody generated from Harbour's integrated G protein-coupled receptor (GPCR) platform. The antibody can enhance antitumor immunity by depleting CCR8 positive regulatory T cells, activating effector T cells.
Medshine Discovery Inc. has presented benzylamino tricyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
Dana-Farber Cancer Institute Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an anaplastic lymphoma kinase (ALK)-targeting moiety through a linker reported to be useful for the treatment of cancer.
